JP2011528551A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011528551A5 JP2011528551A5 JP2011518935A JP2011518935A JP2011528551A5 JP 2011528551 A5 JP2011528551 A5 JP 2011528551A5 JP 2011518935 A JP2011518935 A JP 2011518935A JP 2011518935 A JP2011518935 A JP 2011518935A JP 2011528551 A5 JP2011528551 A5 JP 2011528551A5
- Authority
- JP
- Japan
- Prior art keywords
- dab
- antigen
- seq
- disease
- polypeptide sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8207808P | 2008-07-18 | 2008-07-18 | |
| US61/082,078 | 2008-07-18 | ||
| US16212109P | 2009-03-20 | 2009-03-20 | |
| US61/162,121 | 2009-03-20 | ||
| PCT/US2009/050985 WO2010009391A1 (en) | 2008-07-18 | 2009-07-17 | Compositions monovalent for cd28 binding and methods of use |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014261305A Division JP5876134B2 (ja) | 2008-07-18 | 2014-12-24 | Cd28結合のための一価組成物および使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011528551A JP2011528551A (ja) | 2011-11-24 |
| JP2011528551A5 true JP2011528551A5 (cg-RX-API-DMAC7.html) | 2012-08-30 |
| JP5675608B2 JP5675608B2 (ja) | 2015-02-25 |
Family
ID=41226147
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011518935A Expired - Fee Related JP5675608B2 (ja) | 2008-07-18 | 2009-07-17 | Cd28結合のための一価組成物および使用方法 |
| JP2014261305A Expired - Fee Related JP5876134B2 (ja) | 2008-07-18 | 2014-12-24 | Cd28結合のための一価組成物および使用方法 |
| JP2016009024A Expired - Fee Related JP6058833B2 (ja) | 2008-07-18 | 2016-01-20 | Cd28結合のための一価組成物および使用方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014261305A Expired - Fee Related JP5876134B2 (ja) | 2008-07-18 | 2014-12-24 | Cd28結合のための一価組成物および使用方法 |
| JP2016009024A Expired - Fee Related JP6058833B2 (ja) | 2008-07-18 | 2016-01-20 | Cd28結合のための一価組成物および使用方法 |
Country Status (29)
Families Citing this family (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2006249144B2 (en) | 2005-05-18 | 2011-11-17 | Ablynx Nv | Improved NanobodiesTM against Tumor Necrosis Factor-alpha |
| MX2011000501A (es) | 2008-07-18 | 2011-05-23 | Squibb Bristol Myers Co | Composiciones monovalentes para union a cd28 y metodos de uso. |
| US20110097339A1 (en) * | 2008-07-18 | 2011-04-28 | Domantis Limited | Compositions monovalent for CD28 binding and methods of use |
| CN104017778A (zh) * | 2009-02-25 | 2014-09-03 | 内克斯特伊拉股份公司 | 不依赖信号序列的pIX噬菌体展示 |
| FR2951176A1 (fr) * | 2009-10-09 | 2011-04-15 | Tcl Pharma | Ligands monovalents du recepteur cd28 humain |
| EP2361935A1 (en) * | 2010-02-18 | 2011-08-31 | TcL Pharma | Anti-CD28 humanized antibodies |
| US8785604B2 (en) * | 2010-02-18 | 2014-07-22 | Effimune | Anti-CD28 humanized antibodies |
| CA3220104A1 (en) * | 2010-06-08 | 2011-12-15 | Genentech, Inc. | Cysteine engineered antibodies and conjugates |
| JP5768022B2 (ja) * | 2012-03-19 | 2015-08-26 | 株式会社東芝 | メモリコントローラ、記憶装置、誤り訂正装置および誤り訂正方法 |
| WO2014120916A1 (en) | 2013-02-01 | 2014-08-07 | Bristol-Myers Squibb Company | Pegylated domain antibodies monovalent for cd28 binding and methods of use |
| US10654933B2 (en) * | 2013-12-27 | 2020-05-19 | Chugai Seiyaku Kabushiki Kaisha | Method for purifying antibody having low isoelectric point |
| US20170051059A1 (en) * | 2014-03-19 | 2017-02-23 | Bristol-Myers Squibb Company | Methods of treating transplant rejection using a domain antibody directed against cd40 |
| JP2017531620A (ja) | 2014-09-12 | 2017-10-26 | ジェネンテック, インコーポレイテッド | システイン操作抗体及びコンジュゲート |
| KR20170062505A (ko) | 2014-09-30 | 2017-06-07 | 브리스톨-마이어스 스큅 컴퍼니 | Cd28에 대해 지시된 도메인 항체를 사용하여 전신성 홍반성 루푸스를 치료하는 방법 |
| US20190086405A1 (en) | 2016-03-16 | 2019-03-21 | Bristol-Myers Squibb Company | Methods of diagnosing and treating lupus |
| CA3045944A1 (en) | 2016-12-07 | 2018-06-14 | Progenity, Inc. | Gastrointestinal tract detection methods, devices and systems |
| CA3054632A1 (en) | 2017-03-30 | 2018-10-04 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device |
| MY200973A (en) | 2017-04-11 | 2024-01-26 | Inhibrx Inc | Multispecific Polypeptide Constructs Having Constrained Cd3 Binding And Methods Of Using The Same |
| AU2019234183B2 (en) | 2018-03-15 | 2025-12-18 | Biond Biologics Ltd. | Methods and compositions for decreasing soluble immune receptor CD28 |
| TW202010757A (zh) | 2018-04-11 | 2020-03-16 | 美商英伊布里克斯公司 | 具有經受限cd3結合的多重特異性多肽構築體以及相關方法及用途 |
| WO2019241730A2 (en) | 2018-06-15 | 2019-12-19 | Flagship Pioneering Innovations V, Inc. | Increasing immune activity through modulation of postcellular signaling factors |
| US20230041197A1 (en) | 2018-06-20 | 2023-02-09 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with an immunomodulator |
| US12227565B2 (en) | 2018-06-20 | 2025-02-18 | Biora Therapeutics, Inc. | Method of formulating a pharmaceutical composition comprising administering an immune modulator to the small intestine |
| US12139537B2 (en) * | 2018-06-22 | 2024-11-12 | Junten Bio Co., Ltd. | Antibody inducing immune tolerance, induced lymphocyte, and cell therapy agent therapeutic method using induced lymphocyte |
| WO2020014143A1 (en) * | 2018-07-08 | 2020-01-16 | Specifica Inc. | Antibody libraries with maximized antibody developability characteristics |
| WO2020023553A1 (en) | 2018-07-24 | 2020-01-30 | Inhibrx, Inc. | Multispecific polypeptide constructs containing a constrained cd3 binding domain and a receptor binding region and methods of using the same |
| JP7474240B2 (ja) | 2018-08-03 | 2024-04-24 | ブリストル-マイヤーズ スクイブ カンパニー | 抗薬物抗体を検出するための方法 |
| CN113348011B (zh) | 2018-11-19 | 2023-04-18 | 比奥拉治疗股份有限公司 | 用生物治疗剂治疗疾病的方法和装置 |
| EP3938397A1 (en) | 2019-03-14 | 2022-01-19 | Biond Biologics Ltd. | Small shedding blocking agents |
| MA55805A (fr) | 2019-05-03 | 2022-03-09 | Flagship Pioneering Innovations V Inc | Métodes de modulation de l'activité immunitaire |
| ES2821599A1 (es) * | 2019-10-24 | 2021-04-26 | Univ Del Pais Vasco / Euskal Herriko Unibertsitatea | Compuestos y metodos para el tratamiento de la enfermedad de alzheimer |
| US12612459B2 (en) | 2019-12-02 | 2026-04-28 | Biond Biologics Ltd. | Methods of identifying agents that block MCD28 cleavage by MMPS |
| CN121197633A (zh) | 2019-12-13 | 2025-12-26 | 比特比德科有限责任公司 | 用于将治疗剂递送至胃肠道的可摄取装置 |
| JP2023509359A (ja) | 2019-12-17 | 2023-03-08 | フラグシップ パイオニアリング イノベーションズ ブイ,インコーポレーテッド | 鉄依存性細胞分解の誘導物質との併用抗癌療法 |
| EP4097129A1 (en) * | 2020-01-29 | 2022-12-07 | Inhibrx, Inc. | Cd28 single domain antibodies and multivalent and multispecific constructs thereof |
| KR20220152555A (ko) | 2020-03-12 | 2022-11-16 | 비온드 바이오로직스 엘티디 | 증가된 안정성을 가진 쉐딩 차단제 |
| CN116096906A (zh) | 2020-06-29 | 2023-05-09 | 旗舰创业创新五公司 | 工程化以促进萨诺传递的病毒及其在治疗癌症中的用途 |
| CA3187850A1 (en) | 2020-08-04 | 2022-02-10 | Bryan Glaser | Pd-l1 binding agents and uses thereof |
| EP4313109A1 (en) | 2021-03-31 | 2024-02-07 | Flagship Pioneering Innovations V, Inc. | Thanotransmission polypeptides and their use in treating cancer |
| US20240316104A1 (en) | 2021-06-29 | 2024-09-26 | Flagship Pioneering Innovations V, Inc. | Immune cells engineered to promote thanotransmission and uses thereof |
| EP4399229A2 (en) * | 2021-09-06 | 2024-07-17 | Biond Biologics Ltd. | Cd28 shedding blocking agents |
| EP4519326A4 (en) * | 2022-05-04 | 2026-05-06 | Janux Therapeutics Inc | TUMOR-ACTIVATED MULTISPECIFIC ANTIBODIES TO TARGET CD28 AND PD-L1 AND THEIR METHODS OF USE |
| WO2023215498A2 (en) * | 2022-05-05 | 2023-11-09 | Modernatx, Inc. | Compositions and methods for cd28 antagonism |
| WO2023215560A1 (en) | 2022-05-05 | 2023-11-09 | Atoosa Corporation | Tumor cell/immune cell multivalent receptor engager – bio-nanoparticle (timre-bnp) |
| WO2024040195A1 (en) | 2022-08-17 | 2024-02-22 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
| WO2024077191A1 (en) | 2022-10-05 | 2024-04-11 | Flagship Pioneering Innovations V, Inc. | Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer |
| AU2023356326A1 (en) | 2022-10-06 | 2025-03-27 | Bicara Therapeutics Inc. | Multispecific proteins and related methods |
| WO2024151687A1 (en) | 2023-01-09 | 2024-07-18 | Flagship Pioneering Innovations V, Inc. | Genetic switches and their use in treating cancer |
| WO2024211211A1 (en) | 2023-04-03 | 2024-10-10 | Regeneron Pharmaceuticals, Inc. | Methods of improving transplant survival using il-2 receptor gamma chain antibodies |
| EP4719352A1 (en) | 2023-05-31 | 2026-04-08 | Capstan Therapeutics, Inc. | Lipid nanoparticle formulations and compositions |
| US20250127728A1 (en) | 2023-10-05 | 2025-04-24 | Capstan Therapeutics, Inc. | Constrained Ionizable Cationic Lipids and Lipid Nanoparticles |
| WO2025076113A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Ionizable cationic lipids with conserved spacing and lipid nanoparticles |
| US20250302763A1 (en) | 2024-02-22 | 2025-10-02 | Capstan Therapeutics, Inc. | Immune engineering amplification |
| WO2025217452A1 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2025217454A2 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Ionizable cationic lipids and lipid nanoparticles |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4839295A (en) | 1984-06-08 | 1989-06-13 | Pierce Chemical Company | Measurement of protein using bicinchoninic acid |
| US5977307A (en) | 1989-09-07 | 1999-11-02 | Alkermes, Inc. | Transferrin receptor specific ligand-neuropharmaceutical agent fusion proteins |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| CA2046830C (en) | 1990-07-19 | 1999-12-14 | Patrick P. Deluca | Drug delivery system involving inter-action between protein or polypeptide and hydrophobic biodegradable polymer |
| DE69334275D1 (de) | 1992-08-21 | 2009-05-20 | Univ Bruxelles | Immunoglobuline ohne Leichtkette |
| US6005079A (en) | 1992-08-21 | 1999-12-21 | Vrije Universiteit Brussels | Immunoglobulins devoid of light chains |
| US5922545A (en) | 1993-10-29 | 1999-07-13 | Affymax Technologies N.V. | In vitro peptide and antibody display libraries |
| SE9400088D0 (sv) | 1994-01-14 | 1994-01-14 | Kabi Pharmacia Ab | Bacterial receptor structures |
| US5605793A (en) | 1994-02-17 | 1997-02-25 | Affymax Technologies N.V. | Methods for in vitro recombination |
| GB9416721D0 (en) | 1994-08-18 | 1994-10-12 | Short Brothers Plc | A bias yarn assembly forming device |
| US6346274B1 (en) | 1995-03-10 | 2002-02-12 | Roche Diagnostics Gmbh | Polypeptide-containing pharmaceutical forms of administration in the form of microparticles and method for the preparation thereof |
| EP0859841B1 (en) | 1995-08-18 | 2002-06-19 | MorphoSys AG | Protein/(poly)peptide libraries |
| EP0988321A2 (en) | 1997-06-20 | 2000-03-29 | Innogenetics N.V. | B7-binding molecules for treating immune diseases |
| GB9722131D0 (en) | 1997-10-20 | 1997-12-17 | Medical Res Council | Method |
| AU766959B2 (en) | 1998-04-20 | 2003-10-30 | Genzyme Corporation | Drug delivery of proteins from polymeric blends |
| IL127127A0 (en) | 1998-11-18 | 1999-09-22 | Peptor Ltd | Small functional units of antibody heavy chain variable regions |
| WO2000069907A1 (en) | 1999-05-14 | 2000-11-23 | Medical Research Council | Protein scaffold and its use to multimerise monomeric polypeptides |
| US20020006403A1 (en) * | 1999-12-14 | 2002-01-17 | Xue-Zhong Yu | CD28-specific antibody compositions for use in methods of immunosuppression |
| EP1345969B1 (fr) * | 2000-12-26 | 2010-08-11 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Anticorps anti-cd28 |
| WO2002066059A2 (en) | 2001-02-16 | 2002-08-29 | Genetics Institute, Llc | Agents that specifically block cd28-mediated signaling and uses therefor |
| US20080095774A1 (en) * | 2001-02-16 | 2008-04-24 | Wyeth | Agents and Methods for Specifically Blocking CD28-Mediated Signaling |
| US20030157561A1 (en) | 2001-11-19 | 2003-08-21 | Kolkman Joost A. | Combinatorial libraries of monomer domains |
| US20050089932A1 (en) | 2001-04-26 | 2005-04-28 | Avidia Research Institute | Novel proteins with targeted binding |
| JP4303105B2 (ja) | 2001-06-28 | 2009-07-29 | ドマンティス リミテッド | 二重特異性リガンドとその利用 |
| AU2002319544B2 (en) | 2001-08-10 | 2008-07-10 | Aberdeen University | Antigen binding domains from fish |
| CA2462531A1 (en) | 2001-10-05 | 2003-04-17 | Cangene Corporation | Phagemid display system |
| JP2005289809A (ja) | 2001-10-24 | 2005-10-20 | Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) | 突然変異重鎖抗体 |
| DE10156482A1 (de) * | 2001-11-12 | 2003-05-28 | Gundram Jung | Bispezifisches Antikörper-Molekül |
| CN1678634A (zh) | 2002-06-28 | 2005-10-05 | 多曼蒂斯有限公司 | 免疫球蛋白单个变体抗原结合区及其特异性构建体 |
| NZ540194A (en) | 2002-11-08 | 2008-07-31 | Ablynx Nv | Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor |
| CA2511910A1 (en) | 2002-12-27 | 2004-07-15 | Domantis Limited | Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand |
| AU2004242846A1 (en) | 2003-05-31 | 2004-12-09 | Micromet Ag | Pharmaceutical compositions comprising bispecific anti-CD3, anti-CD19 antibody constructs for the treatment of B-cell related disorders |
| CA2543360A1 (en) | 2003-10-24 | 2005-05-06 | Joost A. Kolkman | Ldl receptor class a and egf domain monomers and multimers |
| CN100376599C (zh) * | 2004-04-01 | 2008-03-26 | 北京安波特基因工程技术有限公司 | 基因工程重组抗cea抗cd3抗cd28线性单链三特异抗体 |
| CN101061140B (zh) * | 2004-09-17 | 2015-07-01 | 多曼蒂斯有限公司 | 单价结合cd40l的组合物和应用方法 |
| GB0614093D0 (en) | 2006-07-14 | 2006-08-23 | Bae Systems Plc | Deployable antenna system |
| US8907065B2 (en) * | 2006-12-15 | 2014-12-09 | Ablynx N.V. | Polypeptides that modulate the interaction between cells of the immune system |
| MX2011000501A (es) * | 2008-07-18 | 2011-05-23 | Squibb Bristol Myers Co | Composiciones monovalentes para union a cd28 y metodos de uso. |
| WO2010020690A1 (en) | 2008-08-21 | 2010-02-25 | Octapharma Ag | Recombinantly produced human factor viii and ix |
| US20170051059A1 (en) * | 2014-03-19 | 2017-02-23 | Bristol-Myers Squibb Company | Methods of treating transplant rejection using a domain antibody directed against cd40 |
| KR20170062505A (ko) * | 2014-09-30 | 2017-06-07 | 브리스톨-마이어스 스큅 컴퍼니 | Cd28에 대해 지시된 도메인 항체를 사용하여 전신성 홍반성 루푸스를 치료하는 방법 |
-
2009
- 2009-07-17 MX MX2011000501A patent/MX2011000501A/es active IP Right Grant
- 2009-07-17 RS RS20190631A patent/RS58904B1/sr unknown
- 2009-07-17 ES ES13185422T patent/ES2730727T3/es active Active
- 2009-07-17 RS RS20160200A patent/RS54675B1/sr unknown
- 2009-07-17 LT LTEP13185422.6T patent/LT2700651T/lt unknown
- 2009-07-17 NZ NZ590343A patent/NZ590343A/xx unknown
- 2009-07-17 SI SI200931964T patent/SI2700651T1/sl unknown
- 2009-07-17 SM SM20190367T patent/SMT201900367T1/it unknown
- 2009-07-17 AU AU2009270726A patent/AU2009270726B2/en not_active Ceased
- 2009-07-17 EP EP13185422.6A patent/EP2700651B1/en active Active
- 2009-07-17 KR KR1020117003660A patent/KR101660057B1/ko not_active Expired - Fee Related
- 2009-07-17 TW TW101147598A patent/TW201336510A/zh unknown
- 2009-07-17 AR ARP090102734A patent/AR072571A1/es active IP Right Grant
- 2009-07-17 US US12/505,166 patent/US8168759B2/en active Active
- 2009-07-17 EA EA201100239A patent/EA024585B1/ru not_active IP Right Cessation
- 2009-07-17 PE PE2011000053A patent/PE20110385A1/es active IP Right Grant
- 2009-07-17 DK DK09790582.2T patent/DK2321352T3/en active
- 2009-07-17 ME MEP-2016-76A patent/ME02396B/me unknown
- 2009-07-17 CN CN2009801358711A patent/CN102159590A/zh active Pending
- 2009-07-17 CN CN201610344002.1A patent/CN105936648B/zh not_active Expired - Fee Related
- 2009-07-17 KR KR1020167025702A patent/KR101791372B1/ko not_active Expired - Fee Related
- 2009-07-17 PT PT97905822T patent/PT2321352E/pt unknown
- 2009-07-17 PE PE2014000192A patent/PE20140852A1/es not_active Application Discontinuation
- 2009-07-17 SI SI200931383T patent/SI2321352T1/sl unknown
- 2009-07-17 WO PCT/US2009/050985 patent/WO2010009391A1/en not_active Ceased
- 2009-07-17 ES ES09790582.2T patent/ES2562629T3/es active Active
- 2009-07-17 CA CA2731220A patent/CA2731220C/en not_active Expired - Fee Related
- 2009-07-17 EP EP09790582.2A patent/EP2321352B1/en active Active
- 2009-07-17 DK DK13185422.6T patent/DK2700651T3/da active
- 2009-07-17 PL PL13185422T patent/PL2700651T3/pl unknown
- 2009-07-17 JP JP2011518935A patent/JP5675608B2/ja not_active Expired - Fee Related
- 2009-07-17 HU HUE13185422A patent/HUE045249T2/hu unknown
- 2009-07-17 PT PT13185422T patent/PT2700651T/pt unknown
- 2009-07-17 TW TW098124305A patent/TWI450725B/zh not_active IP Right Cessation
- 2009-07-17 HR HRP20160329TT patent/HRP20160329T1/hr unknown
- 2009-07-17 HU HUE09790582A patent/HUE029982T2/en unknown
- 2009-07-17 PL PL09790582T patent/PL2321352T3/pl unknown
-
2010
- 2010-12-30 IL IL210413A patent/IL210413A/en active IP Right Grant
-
2011
- 2011-01-18 CL CL2011000117A patent/CL2011000117A1/es unknown
- 2011-02-15 CO CO11017973A patent/CO6341641A2/es active IP Right Grant
-
2012
- 2012-03-09 US US13/415,914 patent/US9085629B2/en active Active
- 2012-03-09 US US13/416,033 patent/US8454959B2/en not_active Expired - Fee Related
- 2012-08-31 CL CL2012002428A patent/CL2012002428A1/es unknown
-
2014
- 2014-12-24 JP JP2014261305A patent/JP5876134B2/ja not_active Expired - Fee Related
-
2015
- 2015-06-16 US US14/740,709 patent/US9908937B2/en not_active Expired - Fee Related
-
2016
- 2016-01-20 JP JP2016009024A patent/JP6058833B2/ja not_active Expired - Fee Related
- 2016-03-29 SM SM201600090T patent/SMT201600090B/xx unknown
-
2017
- 2017-03-21 IL IL251320A patent/IL251320B/en active IP Right Grant
-
2018
- 2018-01-12 US US15/870,121 patent/US10919965B2/en active Active
-
2019
- 2019-05-28 HR HRP20190966TT patent/HRP20190966T1/hr unknown
- 2019-07-09 CY CY20191100722T patent/CY1121796T1/el unknown
-
2020
- 2020-11-02 US US17/086,565 patent/US12012452B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Lykhopiy et al. | IL-2 immunotherapy for targeting regulatory T cells in autoimmunity | |
| JP4628792B2 (ja) | 免疫疾患治療用ラパマイシン及びil−10 | |
| ME02396B (me) | Smješe monovalentne za vezivanje sa cd28 i metodi upotrebe | |
| Zhou et al. | Mesenchymal stem cells: a promising way in therapies of graft-versus-host disease | |
| US10800828B2 (en) | Switchable non-scFv chimeric receptors, switches, and methods of use thereof to treat cancer | |
| AU2014337367B2 (en) | Peptidic chimeric antigen receptor T cell switches and uses thereof | |
| Kim et al. | New strategies for overcoming limitations of mesenchymal stem cell-based immune modulation | |
| Choi et al. | Current and emerging strategies for the prevention of graft-versus-host disease | |
| Mishra et al. | Inflammatory bowel disease: therapeutic limitations and prospective of the stem cell therapy | |
| AU2025237926A1 (en) | Nanoparticle compositions for sustained therapy | |
| JP2024071445A5 (cg-RX-API-DMAC7.html) | ||
| Liu et al. | Il-21 enhances NK cell activation and cytolytic activity and induces Th17 cell differentiation in inflammatory bowel disease | |
| Kebriaei et al. | Treatment of graft-versus-host-disease with mesenchymal stromal cells | |
| JP2010505830A5 (cg-RX-API-DMAC7.html) | ||
| JP2018537962A5 (cg-RX-API-DMAC7.html) | ||
| WO2016168766A1 (en) | Optimized chimeric receptor t cell switches and uses thereof | |
| JP2013508392A5 (cg-RX-API-DMAC7.html) | ||
| CN108883180A (zh) | Clec9a结合剂及其用途 | |
| KR20200047564A (ko) | Clec9a 결합제 및 그의 용도 | |
| Kitagawa et al. | Preclinical development of a WT1 oral cancer vaccine using a bacterial vector to treat castration-resistant prostate cancer | |
| Yang et al. | Therapeutic application of T regulatory cells in composite tissue allotransplantation | |
| Mok et al. | Recent advances and current state of immunotherapy in systemic lupus erythematosus | |
| Ouyang et al. | Recombinant protein Ag85B-Rv2660c-MPT70 promotes quality of BCG-induced immune response against Mycobacterium tuberculosis H37Ra | |
| Cassano et al. | Mesenchymal stem Cell therapy: Clinical progress and opportunities for advancement | |
| JP2013508391A5 (cg-RX-API-DMAC7.html) |